• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.

    8/20/21 4:45:39 PM ET
    $EYEG
    Major Pharmaceuticals
    Health Care
    Get the next $EYEG alert in real time by email
    SC 13G 1 sc13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.   )*
     

     
    EyeGate Pharmaceuticals, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, $0.01 par value per share
     
     
    (Title of Class of Securities)
     

     
    30233M503
     
     
    (CUSIP Number)
     

     
    August 11, 2021
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Fund II LP

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    1,302,933
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    1,302,933
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,302,933(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%
     
    12
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting persons’ ownership consists of (a) 868,622 common shares and (b) warrants to purchase 434,311 common shares (the “Warrants”).



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)

    Lind Global Partners II LLC

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    1,302,933
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    1,302,933
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     1,302,933(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%
     
    12
    Type of Reporting Person (See Instructions)
    OO
     

    (1) The reporting persons’ ownership consists of (a) 868,622 common shares and (b) 434,311 Warrants.

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton

    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    1,302,933
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    1,302,933
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    1,302,933(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     

    (1) The reporting persons’ ownership consists of (a) 868,622 common shares and (b) 434,311 Warrants.

    Item 1.
    (a)
    Name of Issuer
     
     
    EyeGate Pharmaceuticals, Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    271 Waverley Oaks Road, Suite 108
    Waltham, MA 02452

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •  Lind Global Fund II LP, a Delaware limited partnership;
    •  Lind Global Partners II LLC, a Delaware limited liability company; and
    •  Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II, LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities

     
    Common stock, $0.01 par value per share.

    (e)
    CUSIP Number

     
    30233M503
     

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not Applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits     Exhibit

    99.1                  Joint Filing Agreement by and among the Reporting Persons.


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    August 20, 2021
         
    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton




    Get the next $EYEG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EYEG

    DatePrice TargetRatingAnalyst
    8/16/2021$14.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EYEG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Daniels Eric Joseph

      4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      11/10/21 4:17:24 PM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by new insider Daniels Eric Joseph

      3 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

      11/10/21 4:15:33 PM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: From Stephen covered exercise/tax liability with 250 shares, decreasing direct ownership by 0.36% to 68,292 units

      4 - EYEGATE PHARMACEUTICALS INC (0001372514) (Issuer)

      11/3/21 4:16:21 PM ET
      $EYEG
      Major Pharmaceuticals
      Health Care

    $EYEG
    SEC Filings

    See more
    • SEC Form 10-Q filed by Eyegate Pharmaceuticals, Inc.

      10-Q - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      11/15/21 7:30:48 AM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • Eyegate Pharmaceuticals, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - KIORA PHARMACEUTICALS INC (0001372514) (Filer)

      11/8/21 7:32:56 AM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • SEC Form D filed by Eyegate Pharmaceuticals, Inc.

      D - EYEGATE PHARMACEUTICALS INC (0001372514) (Filer)

      11/4/21 4:20:13 PM ET
      $EYEG
      Major Pharmaceuticals
      Health Care

    $EYEG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Eyegate Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eyegate Pharmaceuticals with a rating of Buy and set a new price target of $11.00 from $14.00 previously

      8/16/21 10:16:53 AM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • Alliance Global Partners reiterated coverage on EyeGate Pharmaceuticals with a new price target

      Alliance Global Partners reiterated coverage of EyeGate Pharmaceuticals with a rating of and set a new price target of $16.75 from $15.50 previously

      2/4/21 12:09:11 PM ET
      $EYEG
      Major Pharmaceuticals
      Health Care

    $EYEG
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EYEG
    Leadership Updates

    Live Leadership Updates

    See more
    • AllianceBernstein Launches Five New Active ETFs

      Lineup includes one Buffered product and four Fixed Income products in AB's ETF suite NASHVILLE, Tenn., Dec. 13, 2023 /PRNewswire/ -- AllianceBernstein Holding L.P. (NYSE:AB) and AllianceBernstein L.P., a leading global investment management and research firm, announced today the launch of five active exchange-traded funds (ETFs) on the NASDAQ and New York Stock Exchange (NYSE) Arca: AB Conservative Buffer ETF (NASDAQ:BUFC), AB Tax-Aware Intermediate Municipal ETF (NYSE:TAFM), AB Tax-Aware Long Municipal ETF (NYSE:TAFL), AB Corporate Bond ETF (NASDAQ:EYEG), and AB Core Plus Bond ETF (NASDAQ:CPLS). "On the heels of crossing the $1 billion threshold in active ETF AUM, these new ETFs will prov

      12/13/23 7:30:00 AM ET
      $AB
      $EYEG
      Investment Managers
      Finance
      Major Pharmaceuticals
      Health Care
    • EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company's Sharpened Clinical Development Strategy

      SALT LAKE CITY, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), ("Kiora" or the "Company") is the new name of EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG). Kiora will trade on the Nasdaq Capital Market under the ticker symbol "KPRX" and CUSIP number 49721T101. The new brand reflects the Company's aim to not only treat common eye conditions, but to develop a revolutionary small molecule therapy that has the potential to restore vision loss for a rare, inherited degenerative retinal disease, Retinitis Pigmentosa. The Company's newly revamped clinical development strategy is available in the Investors section of the Company's new website at www.kiorapharma.com. "T

      11/8/21 7:30:00 AM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

      WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. ("Bayon") and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate's pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which acts as a ‘molecular p

      10/26/21 7:00:00 AM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • EyeGate Pharmaceuticals Appoints Eric J. Daniels, MD, MBA, as Chief Development Officer and Closes Acquisition of Bayon Therapeutics, Inc.

      WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that it has completed the planned acquisition of Bayon Therapeutics, Inc. ("Bayon") and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate's pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which acts as a ‘molecular p

      10/26/21 7:00:00 AM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer

      WALTHAM, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG), ("EyeGate" or the "Company"), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system, today announced that Brian M Strem, Ph.D., Co-Founder, Director and former Chief Executive Officer of Okogen, Inc as well as Co-Founder and Managing Director of Bayon Therapeutics, was appointed as permanent President, Chief Executive Officer and board member, effective immediately. He brings strategic expertise, scientific acumen and drug development experience in ophthalmology, otology and regenerative medicine t

      7/26/21 4:15:00 PM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors

      WALTHAM, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing products for treating inflammatory and immune diseases, today announced that it has appointed Kenneth Gayron and Aron Shapiro to the Company’s Board of Directors, effective immediately. Thomas Hancock, Morton Goldberg, M.D., and Bernard Malfroy-Camine, Ph.D., have stepped down from the board, which is now composed of seven members. Both Mr. Gayron and Mr. Shapiro bring a unique perspective, deep expertise and valuable insight to the Company. “We are very pleased to welcome these esteemed leaders to our board as we navigate our

      4/1/21 6:55:00 AM ET
      $EYEG
      Major Pharmaceuticals
      Health Care

    $EYEG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.

      SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)

      8/20/21 4:45:39 PM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.

      SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)

      8/20/21 4:40:06 PM ET
      $EYEG
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Eyegate Pharmaceuticals, Inc.

      SC 13G - EYEGATE PHARMACEUTICALS INC (0001372514) (Subject)

      8/19/21 4:30:56 PM ET
      $EYEG
      Major Pharmaceuticals
      Health Care